Results from a first-of-its-kind study identify a significant increase in the incidence of atrial fibrillation (AF) among patients with pacemaker-detected sleep apnea.
A new study shows the use of novel anticoagulants to treat atrial fibrillation (AF) on an “as needed basis” guided by diligent pulse monitoring can be an effective and safe way to lower overall risk of stroke.
May 9, 2016 — New data presented at the Heart Rhythm Society's (HRS) annual meeting highlighted the long-term safety of ...
Venous thromboembolism (VTE), and pulmonary embolism (PE) in particular, are among the most complex and dangerous acute ...
A new study has found an increased risk of dementia in patients with atrial fibrillation (AF) that receive long-term blood thinner warfarin (Coumadin) compared to patients that use warfarin for conditions other than AF.
May 9, 2016 —St. Jude Medical announced presentation of the MultiPoint Pacing (MPP) Investigational device exemption ...
May 9, 2016 — A new study presented at the Heart Rhythm Society’s 37th Annual Scientific Sessions, found that among ...
Sponsored Content — According to the American Heart Association, cardiovascular disease is the leading cause of death in ...
May 9, 2016 — Medtronic announced the results of several studies evaluating a novel approach to implantable cardioverter ...
May 9, 2016 — The mid to long-term results from the EFFORTLESS study, the largest subcutaneous implantable cardioverter ...
May 9, 2016 – A new, large study shows that 95.7 percent of individual leads were successfully removed using a procedure ...
Cardiac PET/CT represents a major advancement in cardiovascular diagnostics, offering significant clinical and ...
Atrial fibrillation patients taking warfarin are at higher risk of developing kidney failure if anticoagulation levels are not properly managed, according to a new study from researchers at the Intermountain Medical Center Heart Institute.
The largest risk-directed study by a national hospital system demonstrates a 40 percent decline in bleeding events for percutaneous coronary intervention (PCI) patients and a significant reduction in pharmacy costs.
The Society for Cardiovascular Angiography and Interventions (SCAI) has released an expert consensus statement providing cardiologists, oncologists and internal medicine physicians guidance for treating patients facing concomitant cardiovascular disease and cancer.
SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...
May 6, 2016 — Cardiovascular Systems Inc. shared three-year results from its pivotal ORBIT II study in a featured ...
Intact Vascular Inc. announced that positive twelve-month results from its Tack Optimized Balloon Angioplasty – Below-the-Knee (TOBA-BTK) clinical study were presented at the SCAI 2016 conference.
May 5, 2016 — The Society for Cardiovascular Angiography and Interventions (SCAI) published an update to its 2012 paper ...
May 09, 2016
